drugset
drugset / Trial / NCT04737889

Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma

NCT04737889 ↗

Phase 2 Recruiting 30 enrolled Henan Cancer Hospital
NaSingle-groupOpen-labelTreatment

Summary

This is a prospective single arm, multi-center, phase II clinical trial to observe the efficacy and safety of Rituximab, Lenalidomide combined with high-dose Methotrexate and Temozolomide (RL-MT) in the first-line treatment for patients with primary central nervous system lymphoma.

Timeline

Start
2021-01-13
Primary completion
2025-06-30
Completion
2026-01-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 10 mg Oral
Subject Methotrexate Small molecule 3 mg/m2 Intravenous
Subject Rituximab Monoclonal antibody 375 mg/m2 Intravenous
Subject Temozolomide Small molecule 150 mg/m2 Oral

Indications

primary central nervous system lymphoma